Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
GNI Group ( (JP:2160) ) has issued an announcement.
GNI Group Ltd. reported a decrease in revenue and profits for Q1 FY2025 compared to the same period last year, with revenue dropping by 10.6% and a significant decline in profits. The financial results indicate challenges in the company’s operations, impacting its market position and potentially affecting stakeholder confidence.
The most recent analyst rating on (JP:2160) stock is a Buy with a Yen3700.00 price target. To see the full list of analyst forecasts on GNI Group stock, see the JP:2160 Stock Forecast page.
More about GNI Group
GNI Group Ltd. operates in the pharmaceutical industry, focusing on the development and commercialization of innovative drugs. The company is listed on the Tokyo Stock Exchange and is known for its commitment to advancing healthcare solutions.
Average Trading Volume: 2,327,313
Technical Sentiment Signal: Hold
Current Market Cap: Yen124.9B
For an in-depth examination of 2160 stock, go to TipRanks’ Stock Analysis page.